Dual thrombolytic therapy with mutant pro-urokinase and small bolus alteplase for ischemic stroke (DUMAS): study protocol for a multicenter randomized controlled phase II trial

BACKGROUND: The effectiveness of alteplase for ischemic stroke treatment is limited, partly due to the occurrence of intracranial and extracranial hemorrhage. Mutant pro-urokinase (m-proUK) does not deplete fibrinogen and lyses fibrin only after induction with alteplase. Therefore, this treatment ha...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Ende, Nadinda A. M., Roozenbeek, Bob, Smagge, Lucas E. M., Luijten, Sven P. R., Aerden, Leo A. M., Kraayeveld, Petra, van den Wijngaard, Ido R., Lycklama à Nijeholt, Geert J., den Hertog, Heleen M., Flach, H. Zwenneke, Wallace, Alexis C., Gurewich, Victor, del Zoppo, Gregory J., Meurer, William J., Lingsma, Hester F., van der Lugt, Aad, Dippel, Diederik W. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361639/
https://www.ncbi.nlm.nih.gov/pubmed/35945566
http://dx.doi.org/10.1186/s13063-022-06596-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361639/
https://www.ncbi.nlm.nih.gov/pubmed/35945566
http://dx.doi.org/10.1186/s13063-022-06596-z

Ejemplares similares